Home | Clinical Focus | Government to subsidise Leukaemia drug

Government to subsidise Leukaemia drug

Life-changing medication for leukaemia and lymphoma patients will soon be within reach for more than 900 Australians.

Prime Minister Malcolm Turnbull will announce on Monday that Ibrutinib – known as Imbruvica – will be listed on the pharmaceutical benefits scheme from December at a cost of $466 million.

The medicine which normally costs $187,390 per course of treatment will be reduced to $38.80 per script or $6.30 for concessional patients.

It will be available to eligible patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.

Normally Ibrutinib is used when patients have not responded to first line treatment with chemo-immuno-therapy.

Do you have an idea for a story?
Email [email protected]

Get the news delivered straight to your inbox

Receive the top stories in our weekly newsletter Sign up now

Leave a Comment

Your email address will not be published. Required fields are marked *